Febrofid, gel 2.5% 30 g

Ketoprofen belongs to the group of NSAIDs with anti-inflammatory, anti-exudative and analgesic effect.
In the form of gel provides local treatment of joints, tendons, ligaments, muscles, skin, veins, lymph vessels and lymph nodes.

In joint syndrome it relieves pain in the joints at rest and when moving, reduces morning stiffness and joint swelling.

Pharmacokinetics

It penetrates well through the skin. Bioavailability of the gel is about 5%. The absorbed part of ketoprofen binds with blood plasma proteins by about 99%. It is metabolized in the liver. About 80% of the dose taken is excreted in the urine as metabolites, less than 10% – unchanged.

It does not cumulate in the body.

Indications

Used topically as an analgesic and anti-inflammatory drug for symptomatic treatment of:

pain in the spine, neuralgia, myalgia,
inflammatory and degenerative diseases of the musculoskeletal system (including arthritis, bursitis, synovitis, tendinitis, lumbago);
uncomplicated injuries, in particular sports injuries, dislocations, sprains or ruptures of ligaments and tendons, bruises, post-traumatic pain,
as part of combination therapy for inflammatory diseases of the veins (phlebitis, periphlebitis), lymphatic vessels, lymph nodes (lymphangitis, superficial lymphadenitis).

Pharmacological effect

Ketoprofen belongs to the group of NSAIDs that have anti-inflammatory, antiexudative and analgesic effects.
In the form of a gel, it provides local treatment for lesions of joints, tendons, ligaments, muscles, skin, veins, lymphatic vessels and lymph nodes.

In case of articular syndrome, it causes a decrease in joint pain at rest and during movement, a decrease in morning stiffness and swelling of the joints.

Pharmacokinetics

Penetrates well through the skin. The bioavailability of the gel is about 5%. The absorbed part of ketoprofen is approximately 99% bound to plasma proteins. Metabolized in the liver. About 80% of the dose taken is excreted in the urine in the form of metabolites, less than 10% is excreted unchanged.

Does not accumulate in the body.

Active ingredient

Ketoprofen

Composition

Active substance:

Ketoprofen lysine salt,

2.5 g/100.0 g gel

Excipients:

polyethylene glycol,

methylhydroxybenzoate,

propylhydroxybenzoate,

carbomer,

triethanolamine,

purified water.

Pregnancy

In the first and second trimesters of pregnancy, the drug can be used only if necessary. In the third trimester of pregnancy, the use of the drug is contraindicated.

Not recommended for use during breastfeeding.

Contraindications

weeping dermatoses, eczema;
infected abrasions, wounds, burns;
III trimester of pregnancy;
lactation period (breastfeeding);
hypersensitivity to ketoprofen and/or other components of the drug;
hypersensitivity to other NSAIDs (ketoprofen can cause bronchospasm in individuals sensitive to acetylsalicylic acid and other NSAIDs).
Allergic reactions, skin hyperemia, photosensitivity, skin exanthema, purpura.

Side Effects

Allergic reactions, skin hyperemia, photosensitivity, skin exanthema, purpura.

Interaction

With frequent and prolonged use, symptoms of interaction with other drugs may appear (the same as with systemic use).

When taken together with other NSAIDs, corticosteroids, ethanol, corticotropin, the formation of ulcers and the development of gastrointestinal bleeding is possible.

Concomitant use with oral anticoagulants, heparin, thrombolytics, antiplatelet agents, cefoperazone, cefamandole increases the risk of bleeding.

Ketoprofen reduces the effect of antihypertensive drugs and diuretics (inhibition of prostaglandin synthesis).

Increases the hypoglycemic effect of insulin and oral hypoglycemic drugs (dose adjustment required). Co-administration with sodium valproate causes disruption of platelet aggregation. Increases the concentration of verapamil and nifedipine in the blood plasma.

Do not allow the gel to come into contact with mucous membranes or eyes.

The drug should not be applied to damaged areas of the skin.

Caution must be exercised during long-term use in patients with severe renal or hepatic impairment.

If a rash appears, you must stop using the drug and carry out appropriate therapy.

Storage conditions

The drug should be stored in a place protected from light and out of reach of children at a temperature of 15° to 25°C.

Shelf life

2 years.

Manufacturer

Medana Pharma, Poland